Knowledge that BDNF promotes CNS myelination through TrkB signalling suggests it could be targeted as a therapeutic for demyelinating conditions, including stroke, traumatic injury and multiple sclerosis (MS). Here, NTRK2 is linked to myeloid sarcoma.